No HoFH definition could give Aegerion market lead with Juxtapid
This article was originally published in Scrip
There was little question the US FDA would approve Aegerion Pharmaceuticals' Juxtapid (lomitapide), a microsomal triglyceride transfer protein inhibitor intended to treat patients with homozygous familial hyperchodlesterolemia (HoFH) – with that OK coming about a week ahead of its 29 December Prescription Drug User Fee Act action date.
You may also be interested in...
Three and a half months after Ionis Pharmaceuticals Inc. surprised investors with the news that Sanofi's Genzyme business unit would no longer market Kynamro (mipomersen) for homozygous familial hypercholesterolemia (HoFH), the Carlsbad, California-based biotechnology company revealed that it sold global rights to the cholesterol-lowering drug to Kastle Therapeutics LLC for up to $95m.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.